Literature DB >> 10213962

A case of hepatocellular carcinoma with bone metastasis responding to radiotherapy after successful hepatectomy of primary lesion.

T Asahara1, K Dohi, H Hino, H Nakahara, K Katayama, T Itamoto, F Shimamoto, Y Honke.   

Abstract

Radical hepatectomy was carried out on a patient with hepatocellular carcinoma (HCC) located in segment VIII of the liver. The patient was a 56-year-old man who showed positive for hepatitis C antibody and negative for hepatitis B surface antigen. Six months after hepatectomy, a lumbar plane X-ray and computed tomography examination revealed bone metastases in the lumbar vertebrae. The patient was subsequently treated by radiation to the lumbar vertebrae in response to lumbago. The metastatic lesion has been well controlled by radiotherapy on an outpatient basis with no recurrence for 5 years and 3 months. The prognosis of patients with HCC with distant metastases is poor. It is believed that the long survival of this patient can be attributed to successful radiotherapy of the bone metastasis after hepatectomy and the lack of recurrence in the liver.

Entities:  

Mesh:

Year:  1999        PMID: 10213962

Source DB:  PubMed          Journal:  Hiroshima J Med Sci        ISSN: 0018-2052


  3 in total

Review 1.  Current management of hepatocellular carcinoma: an Eastern perspective.

Authors:  Hyung Joon Yim; Sang Jun Suh; Soon Ho Um
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 2.  Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma.

Authors:  Cha Jihye; Seong Jinsil
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 3.  A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.

Authors:  C Rory Goodwin; Vijay Yanamadala; Alejandro Ruiz-Valls; Nancy Abu-Bonsrah; Ganesh Shankar; Eric W Sankey; Christine Boone; Michelle J Clarke; Mark Bilsky; Ilya Laufer; Charles Fisher; John H Shin; Daniel M Sciubba
Journal:  World Neurosurg       Date:  2016-05-13       Impact factor: 2.104

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.